KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ionis Pharmaceuticals (IONS) over the last 15 years, with Q3 2025 value amounting to $107.4 million.

  • Ionis Pharmaceuticals' Gains from Investment Securities rose 13416250.0% to $107.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.2 million, marking a year-over-year increase of 5288.32%. This contributed to the annual value of -$5.6 million for FY2024, which is 11162.74% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Gains from Investment Securities of $107.4 million as of Q3 2025, which was up 13416250.0% from -$18.6 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Gains from Investment Securities ranged from a high of $158.7 million in Q4 2022 and a low of -$18.6 million during Q2 2025
  • For the 5-year period, Ionis Pharmaceuticals' Gains from Investment Securities averaged around $16.6 million, with its median value being $458000.0 (2021).
  • Within the past 5 years, the most significant YoY rise in Ionis Pharmaceuticals' Gains from Investment Securities was 13416250.0% (2025), while the steepest drop was 537705.88% (2025).
  • Over the past 5 years, Ionis Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $440000.0 in 2021, then surged by 35971.36% to $158.7 million in 2022, then tumbled by 68.65% to $49.8 million in 2023, then tumbled by 115.46% to -$7.7 million in 2024, then surged by 1496.39% to $107.4 million in 2025.
  • Its Gains from Investment Securities stands at $107.4 million for Q3 2025, versus -$18.6 million for Q2 2025 and -$1.8 million for Q1 2025.